Alec Nielsen
About Alec Nielsen
Co-Founder & CEO Alec Nielsen
Alec Nielsen is the Co-founder and CEO of Asimov, a synthetic biology company established in 2017. He co-founded Asimov with notable figures such as Chris Voigt, Doug Densmore, and Raja Srinivas. Under Alec's leadership, Asimov aims to advance the field of synthetic biology through the development of innovative genetic engineering technologies.
Alec Nielsen’s Educational Background
Alec Nielsen holds a PhD and has an academic background rooted in synthetic biology and genetic engineering. During his PhD studies, he joined the Voigt lab, where he gained significant research experience and contributed to pioneering projects in the field. His educational journey provided him with a strong foundation in both theoretical and practical aspects of biotechnology.
Alec Nielsen's iGEM Involvement
Alec Nielsen has been extensively involved in the International Genetically Engineered Machine (iGEM) competition. He participated as an undergraduate team member, later taking on roles as a mentor, Jamboree judge, track organizer, and partner. Alec's participation in iGEM highlights his commitment to advancing synthetic biology education and fostering collaborative innovation within the scientific community.
Co-Founding Asimov in 2017
In 2017, Alec Nielsen co-founded Asimov, a company dedicated to the advancement of synthetic biology, with Chris Voigt, Doug Densmore, and Raja Srinivas. The team focuses on designing and developing sophisticated genetic circuits, leveraging cutting-edge technologies to address challenges in biotechnology. Asimov's mission under Alec's leadership is to transform the future of biological engineering.
Development of the Genetic Engineering Platform Cello
Prior to co-founding Asimov, Alec Nielsen played a key role in the development of Cello, a hybrid genetic engineering and computer-aided design platform. Cello integrates genetic engineering with computational tools to streamline the design and testing of genetic circuits. Alec's work on Cello underscores his expertise in merging biotechnology with computational methods to enhance synthetic biology solutions.